A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

One cheerleader is rewriting what determination looks like by pushing boundaries on the mat while managing a chronic sleep ...

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results ...

Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical ...

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Narcolepsy is estimated to affect one in 2,000 people in the United States and some 3 million worldwide, according to the Narcolepsy Network, a non-profit patient advocacy group.

Narcolepsy has disrupted Ms. Higgins’s work and family life. She is married and the mother of three children, but she left her job as a nurse and cannot drive.